<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005199</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 77/08 and SASL 29</org_study_id>
    <secondary_id>SWS-SAKK-77/08</secondary_id>
    <secondary_id>SWS-SASL-29</secondary_id>
    <secondary_id>2009-011884-35</secondary_id>
    <secondary_id>EU-20983</secondary_id>
    <secondary_id>CDR0000657702</secondary_id>
    <nct_id>NCT01005199</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer</brief_title>
  <official_title>Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving sorafenib tosylate together with&#xD;
      everolimus to see how well it works compared with sorafenib tosylate alone in treating&#xD;
      patients with localized, unresectable, or metastatic liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine if sorafenib tosylate with versus without everolimus can stop tumor&#xD;
           progression in patients with localized, unresectable, or metastatic hepatocellular&#xD;
           carcinoma.&#xD;
&#xD;
        -  To evaluate changes in symptom-related and global quality of life (QL) and QL benefit&#xD;
           over the course of trial treatment in these patients.&#xD;
&#xD;
        -  To compare the primary endpoint (i.e., progression-free survival at week 12) to the QL&#xD;
           benefit within 12 weeks from baseline.&#xD;
&#xD;
        -  To evaluate how symptom-related and global QL indicators map on the single summary index&#xD;
           derived from a standardized measure of health status for utility cost analysis.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to WHO performance&#xD;
      status (0 vs 1), disease spread (extrahepatic spread vs non-extrahepatic spread), and center.&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm A (standard treatment): Patients receive oral sorafenib tosylate twice daily for 4&#xD;
           weeks. Courses repeat every 4 weeks in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm B (investigational treatment): Patients receive oral sorafenib tosylate twice daily&#xD;
           and oral everolimus once daily for 4 weeks. Courses repeat every 4 weeks in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Some patients may undergo CT scan or MRI at baseline and at 6 and 12 weeks during study to&#xD;
      assess tumor response, tumor size, and tumor density.&#xD;
&#xD;
      Patients complete quality of life questionnaires at baseline and every 2 weeks for 12 weeks&#xD;
      during study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>during trial treatment and follow-up (max. 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease stabilization (DS)</measure>
    <time_frame>under trial treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease stabilization</measure>
    <time_frame>Duration of DS (CR, PR or SD) will be calculated from the time that measurement criteria are met for the first time until documented tumor progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS will be calculated from randomization until documented tumor progression or death, whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>TTP will be calculated from randomization until documented tumor progression or tumor-related death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from randomization until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events at baseline and during trial treatment</measure>
    <time_frame>All AEs will be assessed according to NCI CTCAE v3.0.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alpha fetoprotein (AFP) level</measure>
    <time_frame>Serum AFP levels will be measured during the therapy, if AFP is ≥ 1.5 x ULN at baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation in patients with chronic hepatitis B or C virus infection</measure>
    <time_frame>Number of patients with HCV/HBV (re)-activation during trial treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between vitamin B12 and overall survival</measure>
    <time_frame>The baseline vitamin B12 value, collected at trial randomization, is correlated to overall survival when dichotomized by the cut-point of 600 ng/L.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Sorafenib standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Sorafenib + everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily</description>
    <arm_group_label>Arm B: Sorafenib + everolimus</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Sorafenib 2 x 400 mg daily</description>
    <arm_group_label>Arm A: Sorafenib standard</arm_group_label>
    <arm_group_label>Arm B: Sorafenib + everolimus</arm_group_label>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma&#xD;
             (HCC)&#xD;
&#xD;
               -  Localized, unresectable, or metastatic disease&#xD;
&#xD;
               -  Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction&#xD;
                  (Child-Pugh score ≤ 7)&#xD;
&#xD;
               -  Stage B or C disease according to the Barcelona Clinic Liver Cancer (BCLC)&#xD;
                  staging classification&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable site of disease (≥ 10 mm in case of a&#xD;
                  non-nodal lesion or with a short axis ≥ 15 mm in case of a lymph node) by&#xD;
                  spiral/multi-slice CT/MRI scan according to revised RECIST criteria&#xD;
&#xD;
          -  No locally advanced disease AND a candidate for radical surgery&#xD;
&#xD;
          -  No known fibrolamellar HCC or mixed cholangiocarcinoma/HCC&#xD;
&#xD;
          -  No clinical symptoms or history of CNS metastases or leptomeningeal disease (no&#xD;
             imaging required)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
          -  Neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 75 x 10^9/L&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  INR ≤ 2&#xD;
&#xD;
          -  Urine dipstick for proteinuria ≤ 1+ OR protein spot urine &lt; 0.6 g/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or localized nonmelanoma skin cancer&#xD;
&#xD;
          -  No history of hemorrhagic or thrombotic cerebrovascular event within the past 12&#xD;
             months&#xD;
&#xD;
          -  No documented variceal hemorrhage within the past 3 months&#xD;
&#xD;
          -  No requirement for anticoagulant therapy except for low-dose anticoagulants for&#xD;
             maintenance of patency of central venous access or prevention of deep vein thrombosis&#xD;
&#xD;
          -  No history or presence of clinically significant acute or unstable cardiovascular,&#xD;
             cerebrovascular, renal, gastrointestinal, pulmonary, endocrine, central nervous&#xD;
             system, or immunological disorders (except for the presence of hepatitis B or C virus&#xD;
             or cirrhosis) within the past 6 months&#xD;
&#xD;
          -  No encephalopathy&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No active infection requiring IV antibiotics&#xD;
&#xD;
          -  No arterial hypertension ≥ 150/100 mm Hg despite therapy&#xD;
&#xD;
          -  No ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any&#xD;
             grade, prolongation of QTc &gt; 500 msec on screening electrocardiogram (ECG), or history&#xD;
             of familial long QT syndrome&#xD;
&#xD;
          -  No repeated paracentesis (more than 1 per month)&#xD;
&#xD;
          -  No psychiatric disorder precluding understanding of information of trial-related&#xD;
             topics, giving informed consent, or interfering with compliance for oral drug intake&#xD;
&#xD;
          -  No concurrent grapefruit, grapefruit juice, or products containing bitter oranges&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  Completed baseline quality of life questionnaire&#xD;
&#xD;
          -  Must be compliant and geographically proximal for follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic anticancer treatment for this disease&#xD;
&#xD;
               -  The following prior therapies are allowed provided previously treated lesions&#xD;
                  remain separate from those to be measured in the current trial and prior&#xD;
                  treatment is completed within the past 4 weeks&#xD;
&#xD;
                    -  Surgery&#xD;
&#xD;
                    -  Liver-directed therapy (e.g., transarterial embolization/chemoembolization&#xD;
                       [limited to 5 treatments], radiofrequency ablation, cryoablation,&#xD;
                       radiotherapy, or percutaneous ethanol injection)&#xD;
&#xD;
          -  No prior organ transplantation&#xD;
&#xD;
          -  No concurrent estrogen-containing supplementary therapy&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation with coumarin derivatives&#xD;
&#xD;
          -  No concurrent elective major surgery&#xD;
&#xD;
          -  No concurrent radiotherapy (concurrent analgesic radiotherapy of non-target lesions&#xD;
             allowed)&#xD;
&#xD;
          -  No concurrent or anticipated need for CYP3A4 inhibitors or inducers, unless the drugs&#xD;
             are medically necessary and no substitutes are available, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Protease inhibitors&#xD;
&#xD;
          -  No concurrent strong CYP3A4 inducers*, including any of the following:&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Continuous dexamethasone (&gt; 2 mg/day for &gt; 7 days)&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifampicin&#xD;
&#xD;
               -  St. John's wort NOTE: *Concurrent antacids allowed provided they are administered&#xD;
                  &gt; 1 hour before or &gt; 1 hour after trial drug administration.&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy or treatment in another&#xD;
             clinical trial within the past 30 days&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No chronic systemic steroids or other immunosuppressive agents&#xD;
&#xD;
          -  No concurrent angiotension converting enzyme inhibitors (ACE-I)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koeberle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Francois Dufour, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyorgy Bodoky, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Szent Laszlo Korhaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Montemurro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHUV Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Cancer Research Center at University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHCVS - Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G; Swiss Group for Clinical Cancer Research (SAKK). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016 May;27(5):856-61. doi: 10.1093/annonc/mdw054. Epub 2016 Feb 15.</citation>
    <PMID>26884590</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

